LEO Pharma A/S and FibroTx LLC Enter Partnership to Explore Non-Invasive Skin Test Technology

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global healthcare company dedicated to helping people
achieve healthy skin, and FibroTx, an Estonia-based bio-tech company
providing innovative tools for personalised dermatology and skin care,
today announced that they have entered a partnership to explore
non-invasive skin test technology.

The partnership marks the first step in an alliance to measure soluble
biomarkers from the skin surface of atopic dermatitis patients using a
non-invasive skin test technology developed by FibroTx in Estonia. The
method can be used to assess disease severity, monitor treatment effects
and can potentially predict treatment outcomes. The alliance strengthens
the endeavors of both companies to improve the lives of atopic
dermatitis patients by developing precision medicine tools with minimal
inconvenience to patients.

“We are excited to work with FibroTx with their novel technology that
will help us measure therapeutic responses to our treatment. It is
especially important to seek less painful skin sampling in patients with
already compromised skin,”
says Per Sprøgel , Vice President,
Medical Science and Safety at Leo Pharma.

“We see the collaboration with LEO Pharma as an important recognition
of the potential of the non-invasive skin diagnostic platform
technologies developed by FibroTx. The alliance with LEO Pharma means a
major strengthening of FibroTx’ efforts in the development of practical
home tests that can improve treatment of atopic dermatitis patients,”

says Pieter Spee, Chief Technology Officer of FibroTx LLC.

FibroTx TAP is a non-invasive ELISA-based (Enzyme Linked Immunosorbent
Assay) platform technology where proteins are captured directly from the
skin surface by biomarker capturing antibodies. TAP is more convenient,
more sensitive and more reproducible than conventional protein-based
technologies. FibroTx SELF is a non-invasive lateral flow-test based
platform technology in which samples swabbed from skin are analyzed in
so-called rapid tests that are read-out by a mobile phone or lateral
flow test reader, depending on application.

– ENDS –

About FibroTx:
FibroTx LLC (Tallinn, Estonia) is a
privately held company focused on the development of non-invasive
molecular diagnostic tests for applications in clinical dermatology and
skin care. FibroTx has developed two proprietary diagnostic platforms,
TAP and SELF, that enable measurements of panels of soluble biomarkers
directly from the skin surface. FibroTx lead programs in clinical
dermatology aim at the development of lateral flow test-based
point-of-care devices that can monitor and guide psoriasis and atopic
dermatitis treatments by patients at home.

About LEO Pharma
LEO Pharma helps people achieve healthy
skin. By offering care solutions to patients in more than 130 countries
globally, LEO Pharma supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, the healthcare company
has devoted decades of research and development to delivering products
and solutions to people with skin conditions. LEO Pharma is
headquartered in Denmark and employs around 5,200 people worldwide.

For more information, visit www.leo-pharma.com
to our YouTube channel: www.youtube.com/leopharmaglobal
us on Twitter: www.twitter.com/leohealthyskin
us at LinkedIn: www.linkedin.com/company/leo-pharma


LEO Pharma
Henrik Kyndlev
3140 6180